Black Hawk Acquisition Corp (BKHA): Shareholders' Equity

Annual figures by period end, from SEC filings.

-$3.85M

As of 2025-11-30

-$4.71M

As of 2026-08-31

2023-11-30 Shareholders' Equity (USD) 2025-11-30

Period ended	Shareholders' Equity	Change YoY	Source filing
2025-11-30	-$3.85M	n/m	2026-03-06, Balance as of period end
2024-11-30	-$2.17M	n/m	2026-03-06, Balance as of period end
2023-11-30	$6.1K	n/a	2025-02-07, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Shareholders' Equity	Change YoY
Black Hawk Acquisition Corp (BKHA)	2025-11-30	-$3.85M	n/m
Pluri Inc. (PLUR)	2026-06-30	-$23.04M	n/m
Champions Oncology, Inc. (CSBR)	2026-04-30	$3.94M	+4.4%
CEL SCI Corp (CVM)	2025-09-30	$15.96M	+24.0%
Atara Biotherapeutics, Inc. (ATRA)	2025-12-31	-$38.50M	n/m
Curis Inc (CRIS)	2025-12-31	$5.46M	n/m
Outlook Therapeutics, Inc. (OTLK)	2025-09-30	-$32.19M	n/m
IN8BIO, Inc. (INAB)	2025-12-31	$27.56M	+90.3%
Inmune Bio, Inc. (INMB)	2025-12-31	$23.52M	-26.7%

Compare BKHA, PLUR, CSBR, CVM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗